Lexeo Therapeutics (LXEO) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 23.5% versus a loss of 60.0%. Lexeo Therapeutics is the larger company by market cap ($263.5 million vs $263.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | SABS |
|---|---|---|
| Share price | $3.21 | $2.89 |
| Market cap | $263.50M | $262.95M |
| 1-day change | -3.02% | +0.35% |
| YTD return | -67.67% | -22.73% |
| 1-year return | -60.02% | +23.50% |
| 5-year return | — | -97.15% |
| EPS (TTM) | $-1.02 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $5.15 |
| 52-week low | $2.98 | $2.10 |
| Distance from 52-week high | -70.79% | -43.88% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +532.40% | +302.77% |
| Average volume | 1.20M | 497.66K |
| Shares outstanding | 82.09M | 90.99M |
| Employees | 63 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed LXEO by 83.5 percentage points over the past year.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
LXEO vs SABS FAQ
Which is bigger, Lexeo Therapeutics or SAB Biotherapeutics?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $263.50M compared with $262.95M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, LXEO or SABS?
SABS returned +23.50% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lexeo Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.